Abstract 1443P
Background
Hypertension is a common adverse drug reaction of using angiogenesis inhibitors targeting the vascular endothelial growth factor pathway, such as bevacizumab or ramucirumab. Moreover, angiogenesis inhibitor-induced hypertension is associated with improved clinical outcomes in various cancers. Here, we retrospectively analyzed these data from FRUTIGA to evaluate whether clinical outcomes were associated with fruquintinib-induced hypertension in advanced G/GEJ adenocarcinoma patients treated with fruquintinib plus paclitaxel.
Methods
FRUTIGA was a randomized, double-blind, placebo-controlled phase 3 study. The treatment arm was given fruquintinib 4 mg orally, once daily for 3 weeks followed by 1 week off, plus paclitaxel 80 mg/m2 intravenously on days 1/8/15 per cycle. Post hoc analyses were conducted in the treatment arm.
Results
351 patients were randomized to fruquintinib plus paclitaxel treatment arm. Among these patients, 59 (16.8%) experienced fruquintinib-induced hypertension. 23 (6.6%) experienced grade 3 or more fruquintinib-induced hypertension. No patient permanently discontinued due to hypertension. These patients had a better clinical outcome than those with no occurrence of fruquintinib-induced hypertension, with higher objective response rates (ORR) of 57.6% (95% CI 44.1%-70.4%) versus 39.4% (95% CI 33.7%-45.2%) (p=0.0136). Progression-free survival (PFS) and overall survival (OS) were 8.08 months (95% CI 6.4-8.3) (p=0.0003) and 11.80 months (95% CI 9.3-16.2) (p=0.0157) in the fruquintinib-induced hypertension group, versus 4.63 months (95% CI 4.6-5.9) and 9.36 months (95% CI 8.4-10.4) in no fruquintinib-induced hypertension group, respectively.
Conclusions
Fruquintinib-induced hypertension was associated with higher ORR, longer PFS and OS in advanced G/GEJ adenocarcinoma patients. The fruquintinib-induced hypertension could potentially be predictive of clinical outcomes for pts with treatment with fruquintinib plus paclitaxel.
Clinical trial identification
NCT03223376.
Editorial acknowledgement
Legal entity responsible for the study
Hutchmed Limited.
Funding
The National Science and Technology Major Project (project no. 2019ZX09301012), the Science and Technology Commission of Shanghai Municipality (Science, Technology and Innovation Action Plan, project no. 17431900100) and Hutchmed Limited.
Disclosure
Q. Liu, S. Fan: Financial Interests, Personal, Full or part-time Employment: Hutchmed Limited. All other authors have declared no conflicts of interest.
Resources from the same session
1505P - Exploratory biomarker analysis of the NEONAX trial for response prediction to perioperative (PO) and adjuvant (A) Gem-nabPac chemotherapy (CTX) in resectable PDAC patients (rPDAC Pts)
Presenter: Anton Lahusen
Session: Poster session 18
1506P - ctDNA testing based on deep NGS predicts treatment efficacy and prognosis in advanced pancreatic cancer patients
Presenter: Tingting You
Session: Poster session 18
1507P - Revolutionizing clinical trials: Harnessing artificial intelligence for optimized phase III studies in pancreatic cancer
Presenter: Marie-Edith Bonneterre
Session: Poster session 18
1509P - Cytokines and ductal pancreatic adenocarcinoma: Exploring their relationship with prognosis and molecular subtypes
Presenter: Laura Gutierrez Sainz
Session: Poster session 18
1510P - Exploration of circulating free bacterial DNA as a biomarker for therapy response in metastatic and locally advanced pancreatic cancer patients treated with systemic chemotherapy
Presenter: Sai Surendran
Session: Poster session 18
1511P - The influence of intratumoral bacteria and peri-operative antibiotic treatment on the outcome of resected pancreatic cancer patients treated with adjuvant gemcitabine-based chemotherapy
Presenter: Steffen Ormanns
Session: Poster session 18
1512P - The role of pancreaticoduodenectomy for octogenarians with pancreatic cancer
Presenter: Keita Sonoda
Session: Poster session 18
1513P - Impact of symptom and functional burden on survival in pancreatic ductal adenocarcinoma (PDAC)
Presenter: Omali Pitiyarachchi
Session: Poster session 18
1514P - A prospective, single-center, randomized, controlled, evaluator-blinded, feasibility clinical trial for efficacy and safety of a non-tissue destructive compact focused ultrasound system with neoadjuvant FOLFIRINOX in locally advanced or borderline resectable pancreatic cancer
Presenter: Jae Young Lee
Session: Poster session 18